|
 |
|
Investment Objective/Strategy - The First Trust NYSE Arca Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology IndexSM.
There can be no assurance that the Fund's investment objectives will be achieved.
-
The NYSE Arca Biotechnology IndexSM is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
-
Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.
-
The index is rebalanced quarterly based upon closing prices on the third Friday in January, April, July & October to ensure that each component stock continues to represent an approximately equal weight in the index.
Ticker | FBT |
Fund Type | Biotechnology |
Investment Advisor | First Trust Advisors L.P. |
Investor Servicing Agent | Bank of New York Mellon |
CUSIP | 33733E203 |
ISIN | US33733E2037 |
Intraday NAV | FBTIV |
Fiscal Year-End | 12/31 |
Exchange | NYSE Arca |
Inception | 6/19/2006 |
Inception Price | $20.00 |
Inception NAV | $20.00 |
Rebalance Frequency | Quarterly |
Gross Expense Ratio* | 0.55% |
Net Expense Ratio* | 0.55% |
* As of 5/1/2020
Expenses are capped contractually at 0.60% per year, at least until April 30, 2021.
Closing NAV1 | $157.58 |
Closing Market Price2 | $157.67 |
Bid/Ask Midpoint | $157.59 |
Bid/Ask Premium | 0.01% |
30-Day Median Bid/Ask Spread3 | 0.07% |
Total Net Assets | $1,835,802,737 |
Outstanding Shares | 11,650,002 |
Daily Volume | 77,682 |
Average 30-Day Daily Volume | 113,431 |
Closing Market Price 52-Week High/Low | $184.84 / $139.08 |
Closing NAV 52-Week High/Low | $184.97 / $139.18 |
Number of Holdings (excluding cash) | 30 |
Past performance is not indicative of future results.
Maximum Market Cap. | $144,247 |
Median Market Cap. | $14,044 |
Minimum Market Cap. | $747 |
Price/Book | 4.71 |
Price/Sales | 6.19 |
Holding |
Percent |
United Therapeutics Corporation |
4.35% |
Bio-Techne Corporation |
4.34% |
Agios Pharmaceuticals, Inc. |
4.27% |
Charles River Laboratories International, Inc. |
4.14% |
IQVIA Holdings Inc. |
4.09% |
Nektar Therapeutics |
4.05% |
Illumina, Inc. |
3.96% |
Gilead Sciences, Inc. |
3.80% |
Amgen Inc. |
3.75% |
Alexion Pharmaceuticals, Inc. |
3.66% |
* Excluding cash.
Holdings are subject to change.
|
2020 |
Q1 2021 |
Q2 2021 |
Q3 2021 |
Days Traded at Premium |
96 |
32 |
2 |
--- |
Days Traded at Discount |
157 |
29 |
5 |
--- |
|
Standard Deviation |
Alpha |
Beta |
Sharpe Ratio |
Correlation |
FBT |
24.62% |
-6.42 |
0.90 |
0.31 |
0.67 |
NASDAQ Biotechnology Index |
22.99% |
-0.74 |
0.88 |
0.57 |
0.70 |
S&P Composite 1500 Health Care Index |
16.03% |
2.59 |
0.73 |
0.88 |
0.84 |
S&P 500 Index |
18.40% |
--- |
1.00 |
0.85 |
1.00 |
Standard Deviation is a measure of price variability (risk). Alpha is an indication of how much an investment outperforms or underperforms
on a risk-adjusted basis relative to its benchmark.Beta is a measure of price variability relative to the market. Sharpe Ratio is a measure
of excess reward per unit of volatility. Correlation is a measure of the similarity of performance.
NASDAQ Biotechnology Index - The Index includes securities of NASDAQ-listed companies classified as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. S&P Composite 1500 Health Care Index - The Index is a capitalization-weighted index of companies classified by GICS as health care within the S&P Composite 1500 Index. S&P 500 Index - The Index is an unmanaged index of 500 stocks used to measure large-cap U.S. stock market performance.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|